In a move to strengthen its pipeline, Biogen has agreed to partner with Sage Therapeutics to develop and commercialise zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders. The deal, which is worth up to US$3.57 B, comes a month after the FDA advisory committee voted against the approval of Biogen’saducanumab, citing an absence of strong evidence supporting the drug’s effectiveness; a formal decision by the FDA is expected in March 2021.